NO323727B1 - Anvendelse av kjemoterapi midler - Google Patents

Anvendelse av kjemoterapi midler Download PDF

Info

Publication number: NO323727B1
Authority: NO; Norway
Prior art keywords: treatment; oxo; patient; fluoro; use according
Prior art date: 1999-12-22

Application number

NO20023026A

Other languages

English (en)

Norwegian (no)

Other versions

NO20023026D0 (no

NO20023026L (no

Inventor

Hans-Herrmann Schulz

Original Assignee

Hans-Herrmann Schulz

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-22

Filing date

2002-06-21

Publication date

2007-07-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7934136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO323727(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-06-21 Application filed by Hans-Herrmann Schulz filed Critical Hans-Herrmann Schulz

2002-06-21 Publication of NO20023026D0 publication Critical patent/NO20023026D0/no

2002-08-20 Publication of NO20023026L publication Critical patent/NO20023026L/no

2007-07-02 Publication of NO323727B1 publication Critical patent/NO323727B1/no

Links

239000012829 chemotherapy agent Substances 0.000 title 1
238000011282 treatment Methods 0.000 claims abstract description 137
230000000699 topical effect Effects 0.000 claims abstract description 47
239000003814 drug Substances 0.000 claims abstract description 38
238000002360 preparation method Methods 0.000 claims abstract description 37
241001465754 Metazoa Species 0.000 claims abstract description 16
239000000203 mixture Substances 0.000 claims abstract description 16
238000011321 prophylaxis Methods 0.000 claims abstract description 16
239000002253 acid Substances 0.000 claims abstract description 9
150000003839 salts Chemical class 0.000 claims abstract description 8
-1 carboxylate salts Chemical class 0.000 claims abstract description 7
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 3
150000001875 compounds Chemical class 0.000 claims description 80
239000000499 gel Substances 0.000 claims description 68
239000000243 solution Substances 0.000 claims description 61
210000004262 dental pulp cavity Anatomy 0.000 claims description 60
210000004268 dentin Anatomy 0.000 claims description 57
238000003780 insertion Methods 0.000 claims description 48
230000037431 insertion Effects 0.000 claims description 48
208000027418 Wounds and injury Diseases 0.000 claims description 35
206010052428 Wound Diseases 0.000 claims description 32
241000894006 Bacteria Species 0.000 claims description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
229940079593 drug Drugs 0.000 claims description 18
239000008188 pellet Substances 0.000 claims description 18
208000028169 periodontal disease Diseases 0.000 claims description 18
201000004328 Pulpitis Diseases 0.000 claims description 17
206010037464 Pulpitis dental Diseases 0.000 claims description 17
201000010099 disease Diseases 0.000 claims description 17
AIJTTZAVMXIJGM-UHFFFAOYSA-N Grepafloxacin Chemical compound C1CNC(C)CN1C(C(=C1C)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 AIJTTZAVMXIJGM-UHFFFAOYSA-N 0.000 claims description 14
229960000642 grepafloxacin Drugs 0.000 claims description 14
229920000742 Cotton Polymers 0.000 claims description 10
239000002904 solvent Substances 0.000 claims description 9
229960003702 moxifloxacin Drugs 0.000 claims description 7
FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims description 7
230000029663 wound healing Effects 0.000 claims description 7
239000000645 desinfectant Substances 0.000 claims description 6
WUWFMDMBOJLQIV-UHFFFAOYSA-N 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid Chemical compound C1C(N)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F WUWFMDMBOJLQIV-UHFFFAOYSA-N 0.000 claims description 5
GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 5
239000000839 emulsion Substances 0.000 claims description 5
229960004954 sparfloxacin Drugs 0.000 claims description 5
DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 claims description 5
XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims description 4
239000007864 aqueous solution Substances 0.000 claims description 4
229960003923 gatifloxacin Drugs 0.000 claims description 4
229960003170 gemifloxacin Drugs 0.000 claims description 4
ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 claims description 4
239000003755 preservative agent Substances 0.000 claims description 4
239000003381 stabilizer Substances 0.000 claims description 4
239000000725 suspension Substances 0.000 claims description 4
239000002562 thickening agent Substances 0.000 claims description 4
229950008187 tosufloxacin Drugs 0.000 claims description 4
102000015728 Mucins Human genes 0.000 claims description 3
108010063954 Mucins Proteins 0.000 claims description 3
QGPKADBNRMWEQR-UHFFFAOYSA-N clinafloxacin Chemical compound C1C(N)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl QGPKADBNRMWEQR-UHFFFAOYSA-N 0.000 claims description 3
229950001320 clinafloxacin Drugs 0.000 claims description 3
229960003376 levofloxacin Drugs 0.000 claims description 3
229940051875 mucins Drugs 0.000 claims description 3
229960000497 trovafloxacin Drugs 0.000 claims description 3
WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 claims description 3
XOQQVKDBGLYPGH-UHFFFAOYSA-N 2-oxo-1h-quinoline-3-carboxylic acid Chemical compound C1=CC=C2NC(=O)C(C(=O)O)=CC2=C1 XOQQVKDBGLYPGH-UHFFFAOYSA-N 0.000 claims description 2
206010062255 Soft tissue infection Diseases 0.000 claims description 2
239000003963 antioxidant agent Substances 0.000 claims description 2
239000012876 carrier material Substances 0.000 claims description 2
239000002738 chelating agent Substances 0.000 claims description 2
239000000515 collagen sponge Substances 0.000 claims description 2
239000002270 dispersing agent Substances 0.000 claims description 2
239000003995 emulsifying agent Substances 0.000 claims description 2
239000006260 foam Substances 0.000 claims description 2
239000002502 liposome Substances 0.000 claims description 2
239000000693 micelle Substances 0.000 claims description 2
210000004053 periapical tissue Anatomy 0.000 claims description 2
LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 claims description 2
239000000080 wetting agent Substances 0.000 claims description 2
150000001735 carboxylic acids Chemical class 0.000 claims 3
239000000546 pharmaceutical excipient Substances 0.000 claims 3
125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims 2
210000000214 mouth Anatomy 0.000 claims 2
GJKOYUNIVIJIEA-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid Chemical compound C12=NC=C(F)C=C2C(=O)C(C(=O)O)=CN1C1=CC=C(F)C=C1F GJKOYUNIVIJIEA-UHFFFAOYSA-N 0.000 claims 1
KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 claims 1
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims 1
230000001133 acceleration Effects 0.000 claims 1
229910052783 alkali metal Inorganic materials 0.000 claims 1
229910052784 alkaline earth metal Inorganic materials 0.000 claims 1
230000001771 impaired effect Effects 0.000 claims 1
150000003378 silver Chemical class 0.000 claims 1
238000009472 formulation Methods 0.000 abstract description 8
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 abstract description 6
208000035143 Bacterial infection Diseases 0.000 abstract description 4
229960003405 ciprofloxacin Drugs 0.000 abstract description 3
125000000217 alkyl group Chemical group 0.000 abstract 3
125000005843 halogen group Chemical group 0.000 abstract 3
FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 abstract 2
YCAZALSUJDPQPP-UHFFFAOYSA-N 4-oxo-3h-quinoline-3-carboxylic acid Chemical class C1=CC=C2C(=O)C(C(=O)O)C=NC2=C1 YCAZALSUJDPQPP-UHFFFAOYSA-N 0.000 abstract 2
GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 abstract 2
239000013543 active substance Substances 0.000 abstract 2
125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 abstract 1
125000002723 alicyclic group Chemical group 0.000 abstract 1
125000003342 alkenyl group Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
150000001602 bicycloalkyls Chemical group 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 1
208000032625 disorder of ear Diseases 0.000 abstract 1
208000030533 eye disease Diseases 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
125000005842 heteroatom Chemical group 0.000 abstract 1
150000004677 hydrates Chemical class 0.000 abstract 1
125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
125000004076 pyridyl group Chemical group 0.000 abstract 1
208000024891 symptom Diseases 0.000 description 82
IDIIJJHBXUESQI-DFIJPDEKSA-N moxifloxacin hydrochloride Chemical compound Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 IDIIJJHBXUESQI-DFIJPDEKSA-N 0.000 description 69
229960005112 moxifloxacin hydrochloride Drugs 0.000 description 69
238000003759 clinical diagnosis Methods 0.000 description 63
238000011049 filling Methods 0.000 description 59
208000002925 dental caries Diseases 0.000 description 38
239000002131 composite material Substances 0.000 description 30
238000000034 method Methods 0.000 description 29
206010017711 Gangrene Diseases 0.000 description 28
230000007547 defect Effects 0.000 description 25
208000015181 infectious disease Diseases 0.000 description 22
238000002347 injection Methods 0.000 description 21
239000007924 injection Substances 0.000 description 21
210000001519 tissue Anatomy 0.000 description 21
239000003242 anti bacterial agent Substances 0.000 description 20
230000003115 biocidal effect Effects 0.000 description 20
229940088710 antibiotic agent Drugs 0.000 description 19
208000004480 periapical periodontitis Diseases 0.000 description 17
230000003239 periodontal effect Effects 0.000 description 17
239000003795 chemical substances by application Substances 0.000 description 16
206010061218 Inflammation Diseases 0.000 description 15
230000004054 inflammatory process Effects 0.000 description 14
230000006378 damage Effects 0.000 description 13
230000000694 effects Effects 0.000 description 12
230000036407 pain Effects 0.000 description 12
201000001245 periodontitis Diseases 0.000 description 12
239000002246 antineoplastic agent Substances 0.000 description 11
229940127089 cytotoxic agent Drugs 0.000 description 11
238000000605 extraction Methods 0.000 description 11
239000000126 substance Substances 0.000 description 11
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 10
210000003298 dental enamel Anatomy 0.000 description 10
230000008569 process Effects 0.000 description 10
206010016717 Fistula Diseases 0.000 description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
230000003890 fistula Effects 0.000 description 9
210000005239 tubule Anatomy 0.000 description 9
LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 description 9
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
230000000844 anti-bacterial effect Effects 0.000 description 8
239000004568 cement Substances 0.000 description 8
238000002604 ultrasonography Methods 0.000 description 8
239000002672 zinc phosphate cement Substances 0.000 description 8
208000025865 Ulcer Diseases 0.000 description 7
230000009286 beneficial effect Effects 0.000 description 7
231100000397 ulcer Toxicity 0.000 description 7
208000003433 Gingival Pocket Diseases 0.000 description 6
241000282412 Homo Species 0.000 description 6
229930182555 Penicillin Natural products 0.000 description 6
239000003178 glass ionomer cement Substances 0.000 description 6
230000035876 healing Effects 0.000 description 6
239000000463 material Substances 0.000 description 6
DYNZICQDCVYXFW-AHZSKCOESA-N trovafloxacin mesylate Chemical compound CS(O)(=O)=O.C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F DYNZICQDCVYXFW-AHZSKCOESA-N 0.000 description 6
229960005021 trovafloxacin mesylate Drugs 0.000 description 6
206010006326 Breath odour Diseases 0.000 description 5
238000001035 drying Methods 0.000 description 5
229960003276 erythromycin Drugs 0.000 description 5
239000010410 layer Substances 0.000 description 5
244000005700 microbiome Species 0.000 description 5
230000035515 penetration Effects 0.000 description 5
239000004354 Hydroxyethyl cellulose Substances 0.000 description 4
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
206010020751 Hypersensitivity Diseases 0.000 description 4
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
239000004098 Tetracycline Substances 0.000 description 4
XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
230000000845 anti-microbial effect Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
210000000988 bone and bone Anatomy 0.000 description 4
235000009508 confectionery Nutrition 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 4
239000007789 gas Substances 0.000 description 4
210000004195 gingiva Anatomy 0.000 description 4
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
230000002757 inflammatory effect Effects 0.000 description 4
210000001847 jaw Anatomy 0.000 description 4
150000002960 penicillins Chemical class 0.000 description 4
230000002980 postoperative effect Effects 0.000 description 4
206010040872 skin infection Diseases 0.000 description 4
210000004872 soft tissue Anatomy 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
235000019364 tetracycline Nutrition 0.000 description 4
150000003522 tetracyclines Chemical class 0.000 description 4
229940040944 tetracyclines Drugs 0.000 description 4
230000035899 viability Effects 0.000 description 4
206010060983 Apical granuloma Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
206010034133 Pathogen resistance Diseases 0.000 description 3
229920001213 Polysorbate 20 Polymers 0.000 description 3
206010048038 Wound infection Diseases 0.000 description 3
206010000269 abscess Diseases 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000006978 adaptation Effects 0.000 description 3
239000000853 adhesive Substances 0.000 description 3
230000001070 adhesive effect Effects 0.000 description 3
239000004599 antimicrobial Substances 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
208000014674 injury Diseases 0.000 description 3
210000004877 mucosa Anatomy 0.000 description 3
244000052769 pathogen Species 0.000 description 3
230000001717 pathogenic effect Effects 0.000 description 3
201000009021 periapical granuloma Diseases 0.000 description 3
210000004261 periodontium Anatomy 0.000 description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
229920001296 polysiloxane Polymers 0.000 description 3
230000008092 positive effect Effects 0.000 description 3
230000008929 regeneration Effects 0.000 description 3
238000011069 regeneration method Methods 0.000 description 3
230000008961 swelling Effects 0.000 description 3
238000007910 systemic administration Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
229930186147 Cephalosporin Natural products 0.000 description 2
NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 2
208000006558 Dental Calculus Diseases 0.000 description 2
239000005770 Eugenol Substances 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
208000014151 Stomatognathic disease Diseases 0.000 description 2
208000031650 Surgical Wound Infection Diseases 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
229940126575 aminoglycoside Drugs 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
230000003385 bacteriostatic effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
239000000920 calcium hydroxide Substances 0.000 description 2
229910001861 calcium hydroxide Inorganic materials 0.000 description 2
239000003518 caustics Substances 0.000 description 2
229960001668 cefuroxime Drugs 0.000 description 2
JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920003086 cellulose ether Polymers 0.000 description 2
229940124587 cephalosporin Drugs 0.000 description 2
150000001780 cephalosporins Chemical class 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
229960005091 chloramphenicol Drugs 0.000 description 2
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
238000004140 cleaning Methods 0.000 description 2
229960002227 clindamycin Drugs 0.000 description 2
KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
208000007147 dental pulp necrosis Diseases 0.000 description 2
201000002170 dentin sensitivity Diseases 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
230000003628 erosive effect Effects 0.000 description 2
229960002217 eugenol Drugs 0.000 description 2
HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
230000002262 irrigation Effects 0.000 description 2
238000003973 irrigation Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
230000009965 odorless effect Effects 0.000 description 2
239000002674 ointment Substances 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
150000003077 polyols Chemical class 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000011477 surgical intervention Methods 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
238000011521 systemic chemotherapy Methods 0.000 description 2
239000011787 zinc oxide Substances 0.000 description 2
SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
241000186361 Actinobacteria <class> Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
208000008822 Ankylosis Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000031729 Bacteremia Diseases 0.000 description 1
208000034309 Bacterial disease carrier Diseases 0.000 description 1
241000606125 Bacteroides Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010007882 Cellulitis Diseases 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
108010078777 Colistin Proteins 0.000 description 1
206010069729 Collateral circulation Diseases 0.000 description 1
244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
208000002064 Dental Plaque Diseases 0.000 description 1
206010012327 Dental necrosis Diseases 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
208000035357 Focal Infection Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241000206672 Gelidium Species 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
206010023198 Joint ankylosis Diseases 0.000 description 1
OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
206010031017 Oral soft tissue infections Diseases 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
206010067268 Post procedural infection Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
206010053692 Wound complication Diseases 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
206010000496 acne Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229920013820 alkyl cellulose Polymers 0.000 description 1
230000007815 allergy Effects 0.000 description 1
210000001909 alveolar process Anatomy 0.000 description 1
229960003022 amoxicillin Drugs 0.000 description 1
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
238000011203 antimicrobial therapy Methods 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000006399 behavior Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000005178 buccal mucosa Anatomy 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229960002682 cefoxitin Drugs 0.000 description 1
WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000010634 clove oil Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229960003346 colistin Drugs 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000002689 dentinogenic effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000035620 dolor Effects 0.000 description 1
229960003722 doxycycline Drugs 0.000 description 1
239000006196 drop Substances 0.000 description 1
239000003221 ear drop Substances 0.000 description 1
229940047652 ear drops Drugs 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
238000005530 etching Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
JIYMVSQRGZEYAX-CWUUNJJBSA-N gemifloxacin mesylate Chemical compound CS(O)(=O)=O.C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 JIYMVSQRGZEYAX-CWUUNJJBSA-N 0.000 description 1
229960001151 gemifloxacin mesylate Drugs 0.000 description 1
201000005562 gingival recession Diseases 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
239000000416 hydrocolloid Substances 0.000 description 1
230000003165 hydrotropic effect Effects 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
238000005470 impregnation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
238000009434 installation Methods 0.000 description 1
230000008407 joint function Effects 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
229960005287 lincomycin Drugs 0.000 description 1
OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
206010025226 lymphangitis Diseases 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
229960000282 metronidazole Drugs 0.000 description 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
229960003128 mupirocin Drugs 0.000 description 1
229930187697 mupirocin Natural products 0.000 description 1
DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
229960000988 nystatin Drugs 0.000 description 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
210000004416 odontoblast Anatomy 0.000 description 1
206010063413 odontogenic cyst Diseases 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
230000035778 pathophysiological process Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
229920000223 polyglycerol Polymers 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
238000004321 preservation Methods 0.000 description 1
238000003825 pressing Methods 0.000 description 1
208000037920 primary disease Diseases 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000012545 processing Methods 0.000 description 1
210000003456 pulmonary alveoli Anatomy 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
150000007660 quinolones Chemical class 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000002271 resection Methods 0.000 description 1
201000004700 rosacea Diseases 0.000 description 1
238000010079 rubber tapping Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
210000004499 secondary dentin Anatomy 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
231100000057 systemic toxicity Toxicity 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000002023 wood Substances 0.000 description 1
229910000165 zinc phosphate Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/50—Preparations specially adapted for dental root treatment
- A61K6/54—Filling; Sealing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/60—Preparations for dentistry comprising organic or organo-metallic additives
- A61K6/69—Medicaments
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oral & Maxillofacial Surgery (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Diabetes (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Materials For Medical Uses (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20023026A 1999-12-22 2002-06-21 Anvendelse av kjemoterapi midler NO323727B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19962470A DE19962470A1 (de)	1999-12-22	1999-12-22	Verwendung von Chemotherapeutika
PCT/EP2000/013155 WO2001045679A2 (de)	1999-12-22	2000-12-22	Verwendung von chemotherapeutika zur topischen behandlung

Publications (3)

Publication Number	Publication Date
NO20023026D0 NO20023026D0 (no)	2002-06-21
NO20023026L NO20023026L (no)	2002-08-20
NO323727B1 true NO323727B1 (no)	2007-07-02

Family

ID=7934136

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20023026A NO323727B1 (no)	1999-12-22	2002-06-21	Anvendelse av kjemoterapi midler
NO20071958A NO331317B1 (no)	1999-12-22	2007-04-17	Anvendelse av moxifloxacin for fremstilling av et medikament for topisk og/eller lokal behandling av sar forarsaket av infeksjoner

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20071958A NO331317B1 (no)	1999-12-22	2007-04-17	Anvendelse av moxifloxacin for fremstilling av et medikament for topisk og/eller lokal behandling av sar forarsaket av infeksjoner

Country Status (21)

Country	Link
US (5)	US8975275B2 (pl)
EP (2)	EP1244434B1 (pl)
JP (1)	JP5414138B2 (pl)
KR (1)	KR100803442B1 (pl)
CN (2)	CN100488950C (pl)
AT (2)	ATE369344T1 (pl)
AU (1)	AU784496B2 (pl)
BR (1)	BR0017041A (pl)
CA (2)	CA2395459C (pl)
CY (1)	CY1106977T1 (pl)
DE (3)	DE19962470A1 (pl)
DK (2)	DK1244434T3 (pl)
ES (2)	ES2218264T3 (pl)
IL (2)	IL150359A0 (pl)
MX (1)	MXPA02006248A (pl)
NO (2)	NO323727B1 (pl)
PL (2)	PL205148B1 (pl)
PT (2)	PT1244434E (pl)
TR (1)	TR200401396T4 (pl)
WO (1)	WO2001045679A2 (pl)
ZA (1)	ZA200205027B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6716830B2 (en)	1998-09-30	2004-04-06	Alcon, Inc.	Ophthalmic antibiotic compositions containing moxifloxacin
US6740664B2 (en)	1998-09-30	2004-05-25	Alcon, Inc.	Methods for treating otic and ophthalmic infections
US6509327B1 (en) *	1998-09-30	2003-01-21	Alcon Manufacturing, Ltd.	Compositions and methods for treating otic, ophthalmic and nasal infections
DE19962470A1 (de)	1999-12-22	2001-07-12	Schulz Hans Herrmann	Verwendung von Chemotherapeutika
WO2004058262A1 (en) *	2002-12-31	2004-07-15	Wockhardt Limited	Benzoquinolizine-2-carboxylic acid-containing compositions
WO2004058303A2 (en) *	2002-12-31	2004-07-15	Wockhardt Limited	Compositions of benzoquinolizine carboxylic acid antibiotic drugs
BRPI0407368A (pt)	2003-02-10	2006-02-14	Bayer Healthcare Ag	tratamento de doenças bacterianas dos órgãos respiratórios mediante aplicação local e fluor-quinolonas.
DE10337191A1 (de) *	2003-08-13	2005-03-17	Bayer Healthcare Ag	Neue Verwendung von Chinolon-Antibiotika
SG144936A1 (en) *	2003-09-10	2008-08-28	Kyorin Seiyaku Kk	7-(4-substituted-3-cyclopropylaminomethyl-1- pyrrolidinyl)quinolonecarboxylic acid derivative
US20050158376A1 (en) *	2003-10-23	2005-07-21	Sardi William F.	Dietary supplement and method of processing same
US20090169585A1 (en) *	2003-10-23	2009-07-02	Resveratrol Partners, Llc	Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity
US7759362B2 (en)	2004-04-21	2010-07-20	Institut Of Medicinal Biotechnology Chinese Academy Of Medical Sciences	Quinolonecarboxylic acid compounds, preparation methods and pharmaceutical uses thereof
CN1244582C (zh)	2004-04-21	2006-03-08	中国医学科学院医药生物技术研究所	喹诺酮羧酸类化合物及其制备方法和医药用途
WO2006134431A1 (en) *	2005-05-03	2006-12-21	Ranbaxy Laboratories Limited	Formate salt of gemifloxacin
US20090306035A1 (en) *	2005-08-26	2009-12-10	Emory University	Compounds and Methods for modulating the Silencing of a Polynucleotide of Interest
DE102005045145A1 (de) *	2005-09-15	2007-03-29	Schülke & Mayr GmbH	Verwendung von Octenidindihydrochlorid in halbfesten Zubereitungen
EP1954307A4 (en)	2005-11-14	2009-12-02	Univ Maryland Biotech Inst	ORAL VACCINES AGAINST MILZBRAND ON SALMONELLA BASE
DE102006029500A1 (de) *	2006-06-27	2008-01-03	Schulz, Hans H.	Verwendung einer antimikrobiellen härtenden Alginatmasse zur topischen Behandlung von Wunden und Entzündungen in der Human-, Zahn- und Veterinärmedizin
DE102007040569A1 (de)	2007-08-28	2009-03-05	Schulz, Hans H.	Verfahren zur Prophylaxe von Karies und Parodontopathien
DE102008022086A1 (de)	2008-05-05	2009-11-12	Schulz, Hans H.	Zweikomponenten-Alginat
EP2409702A1 (en) *	2010-07-21	2012-01-25	Bayer Innovation GmbH	Combination of siloxane and active ingredient for treating dental disorder of hard tissues
US8916528B2 (en)	2011-11-16	2014-12-23	Resveratrol Partners, Llc	Compositions containing resveratrol and nucleotides
CN103087042B (zh) *	2012-03-09	2015-02-18	南京优科生物医药有限公司	西他沙星的盐及制药用途
US9433680B2 (en) *	2013-01-31	2016-09-06	Merz Pharmaceuticals, Llc	Topical compositions and methods for making and using same
US9446131B2 (en)	2013-01-31	2016-09-20	Merz Pharmaceuticals, Llc	Topical compositions and methods for making and using same
US9452173B2 (en)	2013-01-31	2016-09-27	Merz Pharmaceuticals, Llc	Topical compositions and methods for making and using same
US8778365B1 (en)	2013-01-31	2014-07-15	Merz Pharmaceuticals, Llc	Topical compositions and methods for making and using same
MY188541A (en) *	2014-01-29	2021-12-21	Vyome Therapeutics Ltd	Besifloxacin for the treatment of resistant acne
JP6644709B2 (ja) *	2014-04-29	2020-02-12	デンツプライシロナインコーポレーテッド	長期間薬物送達システムによる歯内療法
EP3579891A4 (en) *	2017-02-08	2021-01-06	HKL Medical, LLC	INTRASITE ADMINISTRATION AND DOSAGE PROCEDURES AND PHARMACEUTICAL PRODUCTS FOR USE THEREIN
EP3639826A4 (en) *	2017-06-16	2021-03-03	Kyorin Pharmaceutical Co., Ltd.	Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess
US11376216B2 (en)	2018-01-02	2022-07-05	New York University	Periodontal disease therapy
KR20220080176A (ko) *	2019-10-23	2022-06-14	타이젠 바이오테크놀러지 컴퍼니 리미티드	퀴놀론 카르복실산 유도체

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2387647A1 (fr) *	1977-04-20	1978-11-17	Spad Lab	Pate de traitement endodontique pour l'obturation canalaire de dents
DE3068165D1 (en) *	1980-02-28	1984-07-19	Bbc Brown Boveri & Cie	Valve with damping device for the acoustic vibrations started by the working medium itself
NO156828C (no) †	1980-11-10	1987-12-02	Otsuka Pharma Co Ltd	Analogifremgangsm te for fremstilling av antibakterielt virksomme benzoheterocykliske forbindelser.
JPH089597B2 (ja) *	1986-01-21	1996-01-31	杏林製薬株式会社	選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
US4919939A (en) *	1986-04-29	1990-04-24	Pharmetrix Corporation	Periodontal disease treatment system
JPS6343668A (ja) *	1986-08-07	1988-02-24	ヘキスト・アクチエンゲゼルシヤフト	抗細菌接着フイルムおよびその製造方法
DE3635453A1 (de)	1986-08-07	1988-02-11	Hoechst Ag	Antibakterielle klebefolie
DE3632222A1 (de) *	1986-09-23	1988-04-07	Bayer Ag	Topisch anwendbare zubereitungen von gyrase-inhibitoren
JP2558107B2 (ja)	1986-12-18	1996-11-27	第一製薬株式会社	外用剤
DE3704907A1 (de)	1987-02-17	1988-08-25	Bayer Ag	Topisch anwendbare zubereitungen von gyrase-inhibitoren in kombination mit kortikosteroiden
DE3881939T2 (de) *	1987-02-26	1993-09-30	Daiichi Seiyaku Co	Verwendung von Ofloxacin zur lokalen Behandlung oder Prophylaxe von Beschwerden der Wurzelhaut der Zähne.
US5563138A (en) *	1987-04-16	1996-10-08	Otsuka Pharmaceutical Company, Limited	Benzoheterocyclic compounds
DE3906365A1 (de)	1988-07-15	1990-01-18	Bayer Ag	7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
JPH0737385B2 (ja) *	1989-01-18	1995-04-26	大塚製薬株式会社	外用抗菌剤
US5164402A (en) *	1989-08-16	1992-11-17	Pfizer Inc	Azabicyclo quinolone and naphthyridinone carboxylic acids
US5114718A (en)	1990-09-20	1992-05-19	The Procter & Gamble Company	Sustained release compositions for treating periodontol disease
US5620700A (en) *	1990-10-30	1997-04-15	Alza Corporation	Injectable drug delivery system and method
FR2681863B1 (fr)	1991-09-27	1995-02-03	Rhone Dpc Europ	Solution de sparfloxacine sa preparation et sel la constituant.
TW209865B (pl) *	1992-01-10	1993-07-21	Bayer Ag
JP2913241B2 (ja) *	1993-01-29	1999-06-28	富山化学工業株式会社	徐放性口腔用軟膏
CA2153553A1 (en) *	1994-07-13	1996-01-14	Hidekazu Suzuki	Stable lipid emulsion
EP0871628A1 (en) *	1995-06-06	1998-10-21	Abbott Laboratories	Quinolizinone type compounds
IT1280428B1 (it) *	1995-07-14	1998-01-20	R R A S R L	Composizione farmaceutica per uso topico
CN1116905C (zh) *	1995-09-14	2003-08-06	高景曦	喹诺酮杀菌消炎止血纱布
CN1155382A (zh) *	1995-11-29	1997-07-30	董重里	广谱杀菌消毒剂
WO1997044034A1 (fr)	1996-05-20	1997-11-27	Otsuka Pharmaceutical Co., Ltd.	Remede pour le traitement de l'acne rosacee
JP3378772B2 (ja)	1997-06-23	2003-02-17	松下電工株式会社	コンクリート製円筒管の製造方法
KR100219327B1 (ko) *	1997-08-09	1999-09-01	이서봉	퀴놀론 카르복실산 유도체
US20020037260A1 (en) *	1997-10-16	2002-03-28	Budny John A.	Compositions for treating biofilm
US6017912A (en) *	1998-02-27	2000-01-25	Bussell; Letantia	Topical fluoroquinolone antibiotics in an alcohol and acetone vehicle
DE19814133A1 (de) *	1998-03-30	1999-10-07	Espe Dental Ag	Selbstdesinfizierende Kunststoffe und ihre Verwendung im dentalen und dentaltechnischen Bereich
AR020661A1 (es)	1998-09-30	2002-05-22	Alcon Lab Inc	Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
EP1117406A1 (en) *	1998-09-30	2001-07-25	Alcon Laboratories, Inc.	Antibiotic compositions for treatment of the eye, ear and nose
CN1072498C (zh) *	1998-11-12	2001-10-10	毛和平	一种治疗人体烧伤、烫伤的外用药
CN1072499C (zh) *	1998-12-28	2001-10-10	毛和平	一种治疗人体体表慢性溃疡的外用药
US6262071B1 (en) *	1999-06-29	2001-07-17	Smithkline Beecham Corporation	Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria
DE19962470A1 (de)	1999-12-22	2001-07-12	Schulz Hans Herrmann	Verwendung von Chemotherapeutika
DE10347090A1 (de) *	2003-10-10	2005-05-04	Bayer Cropscience Ag	Synergistische fungizide Wirkstoffkombinationen
EP1563731A1 (en) *	2004-02-12	2005-08-17	Bayer CropScience S.A.	Fungicidal composition comprising a pyridylethylbenzamide derivative and a compound capable of inhibiting the ergosterol biosynthesis
JP5271229B2 (ja)	2009-10-05	2013-08-21	大道産業株式会社	濾過システム

1999
- 1999-12-22 DE DE19962470A patent/DE19962470A1/de not_active Withdrawn
2000
- 2000-12-22 CA CA2395459A patent/CA2395459C/en not_active Expired - Lifetime
- 2000-12-22 BR BR0017041-0A patent/BR0017041A/pt not_active Application Discontinuation
- 2000-12-22 CN CNB008190674A patent/CN100488950C/zh not_active Expired - Lifetime
- 2000-12-22 US US10/168,441 patent/US8975275B2/en not_active Expired - Fee Related
- 2000-12-22 AT AT03028047T patent/ATE369344T1/de active
- 2000-12-22 ES ES00985241T patent/ES2218264T3/es not_active Expired - Lifetime
- 2000-12-22 IL IL15035900A patent/IL150359A0/xx active IP Right Grant
- 2000-12-22 EP EP00985241A patent/EP1244434B1/de not_active Expired - Lifetime
- 2000-12-22 CA CA2717246A patent/CA2717246C/en not_active Expired - Fee Related
- 2000-12-22 CN CN2009101183278A patent/CN101513405B/zh not_active Expired - Fee Related
- 2000-12-22 KR KR1020027008087A patent/KR100803442B1/ko not_active IP Right Cessation
- 2000-12-22 PT PT00985241T patent/PT1244434E/pt unknown
- 2000-12-22 DK DK00985241T patent/DK1244434T3/da active
- 2000-12-22 PT PT03028047T patent/PT1408034E/pt unknown
- 2000-12-22 PL PL357379A patent/PL205148B1/pl unknown
- 2000-12-22 AT AT00985241T patent/ATE261722T1/de active
- 2000-12-22 ES ES03028047T patent/ES2291583T5/es not_active Expired - Lifetime
- 2000-12-22 DE DE50005742T patent/DE50005742D1/de not_active Expired - Lifetime
- 2000-12-22 TR TR2004/01396T patent/TR200401396T4/xx unknown
- 2000-12-22 AU AU21716/01A patent/AU784496B2/en not_active Ceased
- 2000-12-22 JP JP2001546418A patent/JP5414138B2/ja not_active Expired - Fee Related
- 2000-12-22 DK DK03028047.3T patent/DK1408034T4/da active
- 2000-12-22 EP EP03028047A patent/EP1408034B2/de not_active Expired - Lifetime
- 2000-12-22 WO PCT/EP2000/013155 patent/WO2001045679A2/de active IP Right Grant
- 2000-12-22 PL PL387061A patent/PL209943B1/pl unknown
- 2000-12-22 MX MXPA02006248A patent/MXPA02006248A/es active IP Right Grant
- 2000-12-22 DE DE50014553T patent/DE50014553D1/de not_active Expired - Lifetime
2002
- 2002-06-20 IL IL150359A patent/IL150359A/en unknown
- 2002-06-21 ZA ZA200205027A patent/ZA200205027B/en unknown
- 2002-06-21 NO NO20023026A patent/NO323727B1/no not_active IP Right Cessation
2007
- 2007-01-04 US US11/619,823 patent/US20070197501A1/en not_active Abandoned
- 2007-04-17 NO NO20071958A patent/NO331317B1/no not_active IP Right Cessation
- 2007-11-06 CY CY20071101421T patent/CY1106977T1/el unknown
2010
- 2010-08-18 US US12/858,527 patent/US20100330165A1/en not_active Abandoned
2014
- 2014-06-03 US US14/294,874 patent/US20140287028A1/en not_active Abandoned
2015
- 2015-10-05 US US14/875,053 patent/US20160045490A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2004501063A (ja)	2004-01-15
PT1408034E (pt)	2007-11-15
CA2395459A1 (en)	2001-06-28
ES2218264T3 (es)	2004-11-16
ES2291583T5 (es)	2011-09-29
ATE261722T1 (de)	2004-04-15
US20070197501A1 (en)	2007-08-23
BR0017041A (pt)	2002-10-22
CN101513405B (zh)	2012-07-04
PT1244434E (pt)	2004-08-31
IL150359A (en)	2007-12-03
EP1408034B2 (de)	2011-05-25
ATE369344T1 (de)	2007-08-15
DE50014553D1 (de)	2007-09-20
EP1408034B1 (de)	2007-08-08
MXPA02006248A (es)	2002-12-05
CA2717246A1 (en)	2001-06-28
CN101513405A (zh)	2009-08-26
AU2171601A (en)	2001-07-03
DK1408034T3 (da)	2007-12-17
DE50005742D1 (de)	2004-04-22
NO20023026D0 (no)	2002-06-21
WO2001045679A3 (de)	2002-07-18
NO20023026L (no)	2002-08-20
PL209943B1 (pl)	2011-11-30
US20030045544A1 (en)	2003-03-06
DK1244434T3 (da)	2004-07-19
KR20020063257A (ko)	2002-08-01
US8975275B2 (en)	2015-03-10
US20160045490A1 (en)	2016-02-18
NO20071958L (no)	2002-08-20
ES2291583T3 (es)	2008-03-01
EP1244434A2 (de)	2002-10-02
CN100488950C (zh)	2009-05-20
NO331317B1 (no)	2011-11-21
ZA200205027B (en)	2004-03-08
DE19962470A1 (de)	2001-07-12
PL357379A1 (pl)	2004-07-26
CA2717246C (en)	2014-02-11
CN1668598A (zh)	2005-09-14
US20100330165A1 (en)	2010-12-30
CA2395459C (en)	2011-11-01
WO2001045679A2 (de)	2001-06-28
EP1244434B1 (de)	2004-03-17
PL205148B1 (pl)	2010-03-31
AU784496B2 (en)	2006-04-13
TR200401396T4 (tr)	2004-08-23
DK1408034T4 (da)	2011-08-15
IL150359A0 (en)	2002-12-01
JP5414138B2 (ja)	2014-02-12
EP1408034A1 (de)	2004-04-14
CY1106977T1 (el)	2012-09-26
US20140287028A1 (en)	2014-09-25
KR100803442B1 (ko)	2008-02-13

Publication	Publication Date	Title
NO323727B1 (no)	2007-07-02	Anvendelse av kjemoterapi midler
JP2004501063A5 (pl)	2008-02-28
US20110044917A1 (en)	2011-02-24	Dental composition for treating peri-implantitis
AU2005202737B2 (en)	2009-01-22	Use of chemotherapeutic agents
RU2217096C1 (ru)	2003-11-27	Способ посттравматической аутореплантации зубов
KR20130043203A (ko)	2013-04-29	치과 장애 치료용 실록산 및 활성 성분의 조합물

Legal Events

Date	Code	Title	Description
2016-08-15	MM1K	Lapsed by not paying the annual fees